NASDAQ:ITRM

Iterum Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy ITRM

*Your capital is at risk

$0.0300

+0 (+0%)

At Close: Jun 03, 2026

Iterum Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 4.59M and sold 17.32K ITRM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	4.59M shares
● Sell	17.32K shares
93% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Nov 18, 2025 Buy	Ordinary Shares P-Purchase	Dunne Michael W. Director	Director	6 000 Value: $2K
Aug 08, 2025 Buy	Ordinary Shares P-Purchase	Dunne Michael W. Director	Director	15 000 Value: $10.9K
Aug 08, 2025 Buy	Ordinary Shares P-Purchase	Dunne Michael W. Director	Director	15 000 Value: $10.9K
Jul 01, 2025 Buy	Share Option (Right to Buy) A-Award	Coyne Christine Chief Commercial Officer	Officer	200 000 Value: $194.0K
Jul 01, 2025 Buy	Common Stock J-Other	Coyne Christine Insider	Other	0 Value: $0
Jul 01, 2025 Buy	Common Stock J-Other	Coyne Christine Insider	Other	0 Value: $0
Jul 01, 2025 Buy	Share Option (Right to Buy) A-Award	Coyne Christine Chief Commercial Officer	Officer	200 000 Value: $194.0K
Mar 10, 2025 Buy	Common Stock J-Other	Whalen Joseph John Insider	Other	0 Value: $0
Mar 10, 2025 Buy	Common Stock J-Other	Whalen Joseph John Insider	Other	0 Value: $0
Jan 13, 2025 Sell	6.500% Exchangeable Senior Subordinated Note due 2025 J-Other	Hunt Ronald Director	Director	0 Value: $0
Jan 13, 2025 Sell	6.500% Exchangeable Senior Subordinated Note due 2025 J-Other	Hunt Ronald Director	Director	0 Value: $0
Aug 06, 2024 Buy	Ordinary Shares M-Exempt	Dunne Michael W. Director	Director	106 247 Value: $128.6K
Aug 06, 2024 Buy	Warrants (right to buy) M-Exempt	Dunne Michael W. Director	Director	106 247 Value: $128.6K
Aug 06, 2024 Buy	Subscription Rights (right to buy) M-Exempt	Dunne Michael W. Director	Director	212 494 Value: $129.6K
Aug 06, 2024 Buy	Ordinary Shares M-Exempt	Fishman Corey N. Chief Executive Officer	CEO / President	82 613 Value: $100.0K
Aug 06, 2024 Buy	Warrants (right to buy) M-Exempt	Fishman Corey N. Chief Executive Officer	CEO / President	82 613 Value: $100.0K
Aug 06, 2024 Buy	Subscription Rights (right to buy) M-Exempt	Fishman Corey N. Chief Executive Officer	CEO / President	165 226 Value: $100.8K
Aug 06, 2024 Buy	Ordinary Shares M-Exempt	Hunt Ronald Director	Director	182 453 Value: $220.8K
Aug 06, 2024 Buy	Warrants (right to buy) M-Exempt	Hunt Ronald Director	Director	182 453 Value: $220.8K
Aug 06, 2024 Buy	Ordinary Shares M-Exempt	Hunt Ronald Director	Director	65 481 Value: $79.2K
Aug 06, 2024 Buy	Warrants (right to buy) M-Exempt	Hunt Ronald Director	Director	65 481 Value: $79.2K
Aug 06, 2024 Buy	Subscription Rights (right to buy) M-Exempt	Hunt Ronald Director	Director	130 962 Value: $79.9K
Aug 06, 2024 Buy	Subscription Rights (right to buy) M-Exempt	Hunt Ronald Director	Director	130 962 Value: $79.9K
Aug 06, 2024 Buy	Warrants (right to buy) M-Exempt	Hunt Ronald Director	Director	65 481 Value: $79.2K
Aug 06, 2024 Buy	Ordinary Shares M-Exempt	Hunt Ronald Director	Director	65 481 Value: $79.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ITERUM THERAPEUTICS PLC

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company ...

Read Full Profile Here